David Jamieson

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Beatrice Seddon, Sandra J. Strauss, Jeremy Whelan et al. · The Lancet Oncology · 2017 · 527 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

Johanne Bray, J Sludden, Martin J. Griffin et al. · British Journal of Cancer · 2010 · 181 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Yvette Drew, Jonathan A. Ledermann, Geoff Hall et al. · British Journal of Cancer · 2016 · 163 citations · Full text

Medicine, Oncology, Pharmacology +17

Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?

Laura Ogle, James Orr, Catherine E. Willoughby et al. · Journal of Hepatology · 2016 · 139 citations

Medicine, Cancer Biology, Oncology +17

Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

Jane Margetts, Laura Ogle, Stephen L. Chan et al. · British Journal of Cancer · 2017 · 120 citations · Full text

Medicine, Immunology, Oncology +17